Results 51 to 60 of about 1,344,168 (284)

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

Clinical management and long-term outcomes in pulmonary inflammatory myofibroblastic tumor: a 12-Year experience with 14 surgically treated adult patients at a single center

World Journal of Surgical Oncology
Background Pulmonary inflammatory myofibroblastic tumor (PIMT) is a rare, borderline mesenchymal neoplasm with unclear etiology. It carries recurrence risks but lacks robust data on surgical outcomes in adults.
Wenhao Wang, Xuan Wang, Haoxin Liu, Dong Xu, Kaiheng Gao, Yulong Tan, Zhouyi Lu, Wan Posum, Meng Shi, Huijun Zhang, Xiaofeng Chen   +10 more
doaj   +1 more source

Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma [PDF]

, 2020
Uveal melanoma (UM) is the most common primary eye malignancy in adults and up to 50% of patients subsequently develop systemic metastasis. Metastatic uveal melanoma (MUM) is highly resistant to immunotherapy.
Bhushan, Alok, Kaushal, Gagan, Lam, Bao, Link, Emma, Londin, Eric R, Orloff, Marlana, Rochani, Ankit, Sato, Takami, Terai, Mizue   +8 more
core   +1 more source

Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens.
Matthew T. McEvoy, Elizabeth L. Seashore, W. Susan Cheng, Shondra Clay, Jessica A. Casas, Jennifer H. Foster   +5 more
wiley   +1 more source

Tmem119 expression is downregulated in a subset of brain metastasis-associated microglia

BMC Neuroscience
Under pathological conditions, the immune-specialized brain microenvironment contains both resident microglia and bone marrow-derived myeloid cells recruited from peripheral circulation.
Weili Ma, Jack Oswald, Angela Rios Angulo, Qing Chen   +3 more
doaj   +1 more source

Role of LncRNAs in regulating cancer amino acid metabolism

Cancer Cell International, 2021
The metabolic change of tumor cells is an extremely complicated process that involves the intersection and integration of various signal pathways. Compared with normal tissues, cancer cells show distinguished metabolic characteristics called metabolic ...
Yuhong Guo, Bin Lv, Renfeng Liu, Zhengzai Dai, Feifei Zhang, Yiping Liang, Bo Yu, Duo Zeng, Xiao-Bin Lv, Zhiping Zhang   +9 more
doaj   +1 more source

Key signalling nodes in mammary gland development and cancer: the snail1-twist1 conspiracy in malignant breast cancer progression [PDF]

, 2010
Breast cancer is the most common cancer among women, and despite significant advances in diagnosing and treating it, metastatic spread of cancer cells results in a high mortality rate. Epithelial-to-mesenchymal transition (EMT) is an embryonic program in
Foubert, Ellen, De Craene, Bram, Berx, Geert   +2 more
core   +2 more sources

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

Downregulation of KCTD12 contributes to melanoma stemness by modulating CD271

Cancer Biology & Medicine, 2019
Objective Cancer metastasis remains the primary cause of cancer-related death worldwide. In a previous study, we found that levels of BTB/POZ domain-containing protein KCTD12 are lower in metastatic melanoma cells than in parental melanoma cells.
Weiyu Shen, Yumei Li, Bifei Li, Liping Zheng, Xiaodong Xie, Jingqing Le, Yusheng Lu, Tao Li, Fan Chen, Lee Jia   +9 more
doaj   +1 more source

The atypical chemokine receptor Ackr2 constrains NK cell migratory activity and promotes metastasis [PDF]

, 2018
Chemokines have been shown to be essential players in a range of cancer contexts. In this study, we demonstrate that mice deficient in the atypical chemokine receptor Ackr2 display impaired development of metastasis in vivo in both cell line and ...
Brownlie, Demi, Burgoyne, Paul, Burt, Claire L., Fraser, Alasdair R., Graham, Gerard J., Hansell, Christopher A.H., Hayes, Alan J., Lee, Kit Ming, Macleod, Megan K.L., Medina-Ruiz, Laura, Nibbs, Robert J.B., Pingen, Marieke, Wilson, Gillian J.   +12 more
core   +1 more source